Skip to main
VVOS

Vivos Therapeutics (VVOS) Stock Forecast & Price Target

Vivos Therapeutics (VVOS) Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Vivos Therapeutics is well-positioned for long-term success due to positive factors such as a higher share count, strong gross margins, and a multi-billion-dollar market potential. They are actively developing their channel and offering through collaborations and partnerships, potentially leading to high profitability. However, an additional capital infusion may be needed in 2026 and expenses may be temporarily higher due to the transition to a new business model. Despite these risks, the company's potential for strong financial performance in the long-term remains high.

Bears say

Vivos Therapeutics is facing challenges, as its gross margins are trending higher, but there is a lack of clarity on its steady-state gross margin. Despite this, the company's new treatment option, the Vivos System, shows promise in addressing the limited treatment times, durability, and potential symptom reversal of sleep apnea. This is reflected in the company's projections, with a 12-month price target of $3.00 derived from a comparable universe analysis and an EV/Revenue multiple of 3.0x. However, there are risks to reaching this target, including lower than expected sales growth, competition, and regulatory concerns. Additionally, the company's share price target may be impacted by balance sheet/liquidity risks, failure to gain regulatory approvals, and changing macroeconomic factors.

Vivos Therapeutics (VVOS) has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Vivos Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Vivos Therapeutics (VVOS) Forecast

Analysts have given Vivos Therapeutics (VVOS) a Strong Buy based on their latest research and market trends.

According to 2 analysts, Vivos Therapeutics (VVOS) has a Strong Buy consensus rating as of Aug 30, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $2.80, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $2.80, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Vivos Therapeutics (VVOS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.